Alpha-synuclein oligomers: a new hope.

Bengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J. · 2017

Read Alpha-synuclein oligomers: a new hope. by Bengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5663814.txt.

Introduction

Bengoa-Vergniory and co-authors present a review in Acta Neuropathologica. It focuses on alpha-synuclein oligomers in Parkinson's disease. Alpha-synuclein is a protein tied to the disease for two decades. Gene mutations and extra gene copies both cause familial forms. The protein also fills the Lewy bodies found in patient brains. Yet how it harms neurons stayed unclear.

Small clumps called oligomers may be the true toxic form. They form before the fibrils inside Lewy bodies. Evidence suggests they spread in a prion-like way. Until lately, no sensitive test could detect them in tissue. New detection methods now reveal distinct oligomer types in post-mortem brain. The authors review therapies aimed at these clumps.

Catalog record

CREATORBengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE97 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5663814

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Alpha-synuclein oligomers: a new hope By Nora Bengoa-Vergniory, Rosalind F. Roberts, Richard Wade-Martins, Javier Alegre-Abarrategui Published in: Acta Neuropathologica DOI: 10.1007/s00401-017-1755-1 ABSTRACT Alpha-synuclein is a protein implicated in Parkinson’s disease and thought to be one of the main pathological drivers in the disease, although it remains unclear how this protein elicits its neurotoxic effects. Recent findings indicate that the assembly of toxic oligomeric species of alpha-synuclein may be one of the key processes for the pathology and spread of the disease. The absence of a sensitive in situ detection method has hindered the study of these oligomeric species and the role they play in the human brain until recently. In this review, we assess the evidence for the toxicity and prion-like activity of oligomeric forms of alpha-synuclein and discuss the advances in our understanding of the role of alpha-synuclein in Parkinson’s disease that may be brought about by the specific and sensitive detection of distinct oligomeric species in post-mortem patient brain. Finally, we discuss current approaches being taken to therapeutically target alpha-synuclein oligomers and their implications. A BRIEF HISTORY OF ALPHA-SYNUCLEIN AND PARKINSON’S DISEASE Over the past two decades, the pre-synaptic protein alpha-synuclein (a-syn) has been irrefutably tied to the neurodegenerative disorder Parkinson’s disease. First, a genetic link was found to associate a-syn to Parkinson’ disease; the point mutation in SNCA (A53T) was demonstrated to cause autosomal dominant Parkinson’s disease [126] and several other point mutations (A30P, E46K, H50Q, G51D and A53E) have since been shown to cause familial forms of Parkinson’s disease and dementia with Lewy bodies (DLB) [4, 79, 84, 119, 129, 167]. Later, duplication or triplication of the a-syn locus was described in several Parkinson’s disease and DLB families [18, 62, 70, 141] and in a handful of sporadic cases [2]. A gene dosage effect of the synuclein gene (SNCA) has been suggested due to the observation that patients with a triplication have an earlier onset, more severe and faster progressing disease compared to those harbouring duplication of the SNCA locus [18]. An equally important milestone in the field was the identification of a-syn as a component of Lewy bodies in patients with both familial and sporadic forms of the disease [6, 147], providing a direct link between different forms of the disease. Not only did this discovery draw attention to aggregated forms of a-syn as mediators of Parkinson’s disease pathogenesis, but also opened the door to the use of a-syn detection techniques for diagnosis and staging. Although this breakthrough occurred 20 years ago, research to date has not been able to describe the exact mechanism by which a-syn accumulates causes neuronal loss and leads to the development of the disease. Multiple lines of evidence now suggest that oligomeric species of a-syn, which are thought to precede the fibrillar aggregates found in Lewy bodies, are the culprits for neuronal degeneration in Parkinson’s disease [59, 162]. In this review, we will discuss the evidence supporting the toxicity of a-syn oligomers in Parkinson’s disease and possible mechanisms for this toxicity, current methods for neuropathological analysis of a-syn oligomer deposition, recent findings indicating the prion-like spread of a-syn and possible therapeutic avenues targeting a-syn oligomers. A-SYN OLIGOMERS AND NEUROTOXICITY Lewy bodies: famously guilty or innocently accused? The presence of fibrillar a-syn in Lewy bodies brought attention to the potential involvement of aggregated a-syn in Parkinson’s disease. However, several lines of evidence suggest that Lewy bodies themselves may be ‘innocent bystanders’ in Parkinson’s disease pathogenesis and that the toxic species of a-syn is in fact oligomers, which are precursors to Lewy bodies and not as readily detectable in histological sections [17]. First, Lewy bodies have been found post-mortem in neurologically normal individuals at the surprisingly high rate of approximately 10% in those over 60 [48, 118]. Second, the Lewy body load in patients has been shown to correlate poorly with the severity of symptoms such as cognitive impairment and dementia [26, 117]. Finally, Parkinson’s disease patients carrying familial mutations in the parkin gene, and some of those with the LRRK2 G2019S mutation, show neuronal degeneration in the absence of Lewy body formation [28, 50]. Together with direct evidence demonstrating the toxicity of oligomeric forms of a-syn, described in the following section, these observations suggest that Lewy bodies form as a protective mechanism by acting as a sink for toxic oligomers, sequestering them away from the cellular machinery [13, 108, 144]. Structure and toxicity of a-syn oligomers The term “oligomer” is widely used to describe aggregated a-syn that has not acquired a fibrillar conformation. The term itself is unspecific as to the molecular composition of a-syn oligomers, which encompass a wide spectrum of molecular weights, and vary in their beta-sheet content and exposed hydrophobicity. It was reported that while low molecular weight and unstable oligomers only had marginal seeding effects, large and stable oligomers were elongated and had high seeding properties [122]. Ghosh et al. have proposed that a-syn goes through a helix-rich intermediate before forming fibrils, which suggests oligomers could have a highly helical structure [52], and according to a recent biophysical study, a common feature a-syn oligomers is a “hollow cylinder” morphology [21]. Also, different mutations in the SNCA gene can influence the structure of their oligomers; A30P mutants form annular pore-like structures while A53T forms annular and tubular structures [80]. Oligomers developed through different protocols have also been shown to elicit different toxic effects: in agreement with Pieri et al., Danzer et al. described in 2007 that small annular oligomers were able to provoke calcium influx, caspase activation and cell death in vitro but had a low seeding capacity, whereas larger oligomers were not toxic but could seed further inclusions [30]. This highlights the heterogeneity of oligomers prepared through different protocols. It is also important to note that while experimental preparations of oligomers are highly enriched for this species, monomers, oligomers and fibrils (and probably other intermediate forms) live in equilibrium and that they constantly aggregate and disaggregate [29], making it difficult to categorically assign experimental effects to one species. Amounting evidence indicates that a-syn oligomers are toxic. Not only are they present at the degenerating regions in Parkinson’s disease patients [140, 151] and transgenic models [53, 64, 66, 121], but direct experimental evidence shows their toxic properties. In vitro formed a-syn oligomers ectopically applied to cell cultures or formed due to over-expression of a-syn induce cell death [20, 30, 109, 149], which has been recapitulated in vivo in several studies. First, expression of a-syn mutants rationally designed to reduce fibril propensity and increase oligomer formation was toxic to immortalised cell lines, primary cultures of rat neurons and dopaminergic neurons of C. elegans and Drosophila [71]. Similarly, Winner et al. showed that expression of E57K and E35K a-syn resulted in conformationally trapped oligomers that were unable to fibrilize and induced neurodegeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) of rats [162]. In contrast, a-syn 30–110 that forms fibrils at a fast rate, did not display toxicity, indicating that oligomers are indeed the toxic species leading to TH-neuron loss in vivo [162]. The study of Winner et al. raises interesting insights into the possible presence and the potential for increased toxicity of ‘off-pathway’ oligomers, which do not

Read the complete text